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Running title: Gene expression in a small vessel disease model 
 
Abstract 
Aims: Cerebral small vessel disease (SVD) causes a fifth of all strokes plus diffuse brain 
damage leading to cognitive decline, physical disabilities and dementia. The aetiology and 
pathogenesis of SVD are unknown, but largely attributed to hypertension or microatheroma. 
Methods: We used the spontaneously hypertensive stroke-prone rat (SHRSP), the closest 
spontaneous experimental model of human SVD, and age-matched control rats kept under 
identical, non-salt-loaded conditions, to perform a blinded analysis of mRNA microarray, 
qRT-PCR and pathway analysis in two brain regions (frontal and midcoronal) commonly 
affected by SVD in the SHRSP at age five, 16 and 21 weeks.  
Results: We found gene expression abnormalities, with fold changes ranging from 2.5 to 59 
for the 10 most differentially expressed genes, related to endothelial tight junctions 
(reduced), nitric oxide bioavailability (reduced), myelination (impaired), glial and microglial 
activity (increased), matrix proteins (impaired), vascular reactivity (impaired) and albumin 
(reduced), consistent with protein expression defects in the same rats. All were present at 
age 5 weeks thus pre-dating blood pressure elevation. ‘Neurological’ and ‘inflammatory’ 
pathways were more affected than ‘vascular’ functional pathways.  
Conclusions: This set of defects, although individually modest, when acting in combination 
could explain the SHRSP’s susceptibility to microvascular and brain injury, compared with 
control rats. Similar combined, individually modest, but multiple neurovascular unit defects, 
could explain susceptibility to spontaneous human SVD. 
Keywords: blood brain barrier; neurovascular unit; small vessel disease; stroke, lacunar 
stroke,  
Abbreviations: small vessel disease (SVD); gene expression A
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Introduction 
Stroke is the second commonest cause of death and commonest cause of dependency in 
adults worldwide. A fifth of all strokes, a quarter of all ischaemic strokes, are lacunar in type 
and part of the spectrum of cerebral small vessel disease (SVD) [1]. SVD also causes 
cognitive and physical disabilities [2], doubles the risk of dementia and trebles the risk of 
stroke [3].  
Cerebral SVD affects the penetrating arterioles supplying the cerebral white and deep grey 
matter [1]. Human pathology, often late stage and thus hard to unravel [4], includes arteriolar 
vessel wall thickening, perivascular inflammation, arteriolar wall disintegration [5] and 
perivascular damage particularly oedema and demyelination [6] commonly considered to be 
a consequence of ischaemia [4]. Hypertension is the main known vascular risk factor for SVD 
[7]. However, some individuals with pathological evidence of SVD lacked evidence of having 
been hypertensive in life [8], and trials of antihypertensive drugs have had mixed success in 
preventing SVD progression [9-11]. 
We considered that examination of different potential SVD mechanisms in experimental 
models might provide insight into pathogenesis of human SVD. Although several models 
exist we focused on the spontaneously hypertensive stroke-prone rat (SHRSP), which is 
genetically stable and known to mimic spontaneously the human microvascular and brain 
tissue changes [12, 13]. The SHRSP was bred from the Wistar-Kyoto rat (WKY) via the 
spontaneously hypertensive rat (SHR) [14]. It starts to develop hypertension after six weeks 
of age and strokes begin to occur from around 20 weeks [12]. It develops lipohyalinosis and 
fibrinoid necrosis, small deep infarcts, haemorrhages, white matter abnormalities, and 
perivascular space enlargement spontaneously that resemble the pathological changes 
associated with human SVD [12, 14]. Although traditionally attributed to hypertension, we 
found differences in protein expression in SHRSPs (versus age-matched WKY controls) at 
only five weeks of age, that is before blood pressure rises, which persist at 16 and 21 weeks 
of age [15]. These endothelial, glial, astrocyte, microglial and matrix protein abnormalities A
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provide a potential mechanism to explain the SHRSP’s vulnerability to cerebral 
microvascular and parenchymal damage [15].   
Components of human SVD are highly heritable, but so far human genome-wide association 
studies (GWAS) have identified few genes associated with white matter hyperintensities 
(mostly of unknown function) and none so far for lacunar stroke [16-18]. The genetic factors 
that render the SHRSP stroke-prone are also poorly understood. Known differences between 
SHRSP and WKY include STR-2 quantitative trait loci on chromosome 5 co-localised with 
genes encoding atrial and brain natriuretic peptides [19-21], a single nucleotide 
polymorphism (SNP) on chromosome 2 (R202H) associated with reduced glutathione S-
transferase expression [22], and, from a recent GWAS, a number of candidate genes for 
hypertension in spontaneously hypertensive rat substrains [23], but which are not known to 
affect stroke directly [24]. 
We hypothesised that the predisposition of SHRSP to cerebral microvascular and brain 
tissue pathology is multifactorial, involves several pathways, with no single genetic defect 
accounting for all the structural and pathological changes. We assessed mRNA expression in 
the brain by microarray, quantitative reverse transcriptase polymerase chain reaction (qRT-
PCR) and pathway analysis in SHRSP and WKY fed a normal diet at 5, 16 and 21 weeks in 
the two brain regions (frontal and mid-coronal), that are known to express maximal pathology 
[15].  
 
Materials and Methods 
Animals and tissue: All animals were kept and experiments conducted according to UK 
regulations for live animal research in licensed laboratories (licence no 60/3618) and 
conducted according to the ARRIVE (Animal Research: Reporting In Vivo Experiments) 
guidelines (http://www.nc3rs.org/ARRIVE). We also report our results according to the 
Minimum Information About a Microarray Experiment (MIAME) 2.0 criteria 
(http://www.mged.org/Workgroups/MIAME/miame_2.0.html).  A
cc
ep
te
d 
A
rti
cl
e
 
 This article is protected by copyright. All rights reserved.  
5 
SHRSP rats were considered the most appropriate model of human SVD available based on 
a detailed systematic review undertaken within the lab [12]. It is accepted that no animal 
model will ever truly and completely represent a human disease, but the data generated from 
a carefully chosen model can inform and focus subsequent translational research.   
We used four male SHRSPGla (designated SHRSP) and WKYGla (designated WKY) animals 
in each of three age groups (5, 16 and 21 weeks, total animals n=24) from the Glasgow 
colony, the same animals having been used to generate earlier immunohistochemistry data, 
thereby providing a direct intra-animal immunohistochemistry-mRNA comparison. 5 week old 
animals were considered pre-hypertensive as SHRSP have consistently not shown any 
difference in BP until after 6 weeks in SHRSP from this colony in prior work compared with 
control rats [25], with BP measurements always taken from conscious animals. We 
considered 15 week old rats to represent established hypertension, and 21 weeks as an age 
at which strokes were commonly seen to start. We kept all animals in identical conditions and 
fed both strains on standard rat chow ad libitum (Rat and Mouse No. 1 Maintenance Diet, 
Special Diet Services). We used tail cuff plethysmography to take measurements of systolic 
blood pressure on a weekly basis in older rats. We sacrificed animals by overdose of 
isofluorane anaesthetic plus exsanguination. We preserved one cerebral hemisphere in 
formalin and the other hemisphere in liquid nitrogen for mRNA analysis as previously 
described [15]. For mRNA analysis, we immersed each frozen hemisphere in x10 volume of 
RNA-later ice solution and incubated for 24 hours at -20°C so that the following day 2mm 
coronal slices from a frontal and a mid coronal region could be taken using a Zivic® rat slicer 
matrix (Zivic Instruments, Pittsburgh PA, USA) which captured the frontal cortex, thalamus, 
internal capsule and basal ganglia. These represent the areas most susceptible to cerebral 
and vascular pathology in the SHRSP [12]. 
RNA extraction: We placed each coronal slice in approximately 1.5ml (x10 volume) of lysis 
buffer (Qiazol) and homogenized the tissue using a POLYTRON® homogenizer (Capitol 
Scientific Inc., Austin TX, USA). We extracted RNA using a Qiagen RNAeasy lipid tissue 
minikit (Qiagen Ltd. Manchester, UK). We eluted the resulting RNA with nuclease free water 
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(2x50µl). We treated half the elute with turbo DNase to remove any remaining genomic DNA 
and assessed the quality of the resulting RNA on a Nanodrop 1000 and Agilent® bioanalyser 
2100 (Agilent, Santa Clara CA, USA).  
RNA amplification and purification: We performed transcriptions from RNA to cRNA using an 
Ambion® Illumina® Total Prep RNA amplification kit (Applied Biosystems, Foster City CA, 
USA). We generated first strand cDNA with a first strand master mix containing an oligo (dT) 
tagged with a phage T7 promotor and second strand cDNA with a master mix containing 
DNA polymerase. We added the in vitro master mix solution to the elute according to kit 
instructions to amplify and label the cDNA with biotin UTP. We obtained a final cRNA elute of 
~200µl and checked cRNA quality on the Agilent® bioanalyser.  
Microarray mRNA expression analysis: We added 5µl of cRNA (~750ng) to 10µl of 
hybridisation buffer and loaded the resulting 15µl onto a RatRef12 microarray chip (Illumina, 
San Diego, CA, USA), containing 22,519 gene and probe sets. We incubated chips at 58°C 
overnight, washed them with E1BC solution and stained them in a solution of E1 buffer plus 
1:1000 dilution of streptavidin-Cy3. We scanned chips on an Illumina® Bead Reader 
(Illumina, San Diego, CA, USA) and recorded the intensity of fluorescent signal emitted. 
Samples with a signal intensity of >600 passed the bead array reader’s quality control. We 
randomized samples throughout the entire microarray protocol and all samples were 
hybridized to the chips and scanned at the same time.  
qRT-PCR: Using the same DNase-treated RNA from the microarray experiment as the 
template for the synthesis of cDNA, we performed qRT-PCR reactions using Applied 
Biosystems Taqman® Gene Expression Assay (Applied Biosystems, Foster City CA, USA) to 
quantitatively confirm differential expression measured in the microarray experiment. Briefly, 
we reverse transcribed 20 µl reactions on a 96 well plate containing approximately 1µg of 
RNA using the Taqman® reverse transcription master mix (Applied Biosystems, Foster City 
CA, USA) including OligodT primers and Multiscribe™ reverse transcriptase enzyme. We 
performed qRT-PCR on the cDNA by creating a reaction mix in the same Eppendorf 
containing Taqman® universal master mix (Applied Biosystems, Foster City CA, USA) plus a 
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probe for a housekeeping (control) gene (Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (VIC® labelled)) and the Taqman® probe corresponding to our gene of interest 
(FAM® labelled). We ran samples on a 384 well plate on a 7900HT Sequence detector 
(Applied Biosystems, Foster City CA, USA).  
Standard PCR: We designed forward and reverse primers corresponding to the portion of the 
GUCY1a3 gene sequence covered by the Illumina® microarray probe. To test for insertions 
or deletions within the sequence between strains we ran end point PCR using these primers, 
on DNA taken from the livers of additional SHRSP (n=4) and WKY (n=3). We used ‘Kod Hot 
Start’ DNA polymerase (Novagen, Merck, Darmstadt, Germany) and performed PCR 
reactions using the designated kit and to manufacturer’s instructions. Extension times 
depended on the length of sequence being created. We performed all PCR reactions on a 
MJ Research Peltier Thermal Cycler (www.mj-research.com) using 96 well plates. We 
analysed results using agarose gel electrophoresis. We visualised gels on a Bio-Rad Fluor-S 
Multimager and assessed the size of PCR products using Promega 100bp or 1kb DNA 
ladders (Promega, Madison WI, USA).   
DNA Sequencing: We used Applied Biosystems BigDye Terminator n3.1 Cycle Sequencing 
kits (Applied Biosystems, Foster City CA, USA) for all sequencing reactions and performed 
reactions in 96 well plates (SHRSP n=2, WKY n=3 taken from the samples used for standard 
PCR). We loaded a reaction solution of sequencing buffer, ready reaction, primer, purified 
PCR product and water into each well. To sequence, we used a temperature cycling program 
of 96°C for 45 seconds, 50°C for 25 seconds and 60°C for 4 minutes, repeated 25 times. We 
performed sequencing capillary electrophoresis on a 48-capillary Applied Biosystems 3730 
Genetic Analyser with 36cm capillaries filled with POP-7 polymer (Applied Biosystems, 
Foster City CA, USA) and warmed to 60°C. We separated sequencing products by size using 
electrophoresis set to 8500V for 50 minutes.  
Data analysis 
Microarray data: We analysed data using Rank Products (RP) analysis, a non-parametric 
statistical technique [26] complete with Bejamini-Hochberg false discovery rate (FDR) 
A
cc
ep
te
d 
A
rti
cl
e
 
 This article is protected by copyright. All rights reserved.  
8 
adjustment for multiple testing. FDR<0.05 was considered significant. We did not set a 
minimum individual fold change for significance as we were interested in pathway 
interactions. We first generated Venn diagrams to visualize the results by age and brain 
section, then uploaded focus genes onto the Ingenuity Pathway Analysis® (IPA) (Ingenuity 
Systems, www.ingenuity.com) and analysed data using both a pre-specified candidate gene 
approach (looking for changes in genes and pathways thought to be relevant from previous 
work by ourselves and others) and a genome wide approach (to generate new hypotheses). 
Significance of pathways was assessed using 1-sided Fisher’s exact tests. 
qRT-PCR data: we exported cycle threshold (CT) values from sequence detection system 
(SDS) software into a Microsoft® Excel spreadsheet and compared the mean delta cycle 
threshold (dCT) values versus the housekeeper gene (Student’s t test). From these values, 
we calculated and plotted the delta dCT (ddCT) and relative quantification of mRNA 
expression changes (2^ddCT) values.    
Sequencing data: We analysed sequencing using Applied Biosystems SeqScape® software 
and aligned experimental sequences with known sequences derived from bioinformatic 
databases such as ENSEMBL genome browser (http://www.ensembl.org/index.html).   
 
Results 
At 5 weeks (prior to any rise in blood pressure), there were more differentially expressed 
genes between SHRSP and WKY than at 16 or 21 weeks: 162 were differentially expressed 
in both brain regions, plus 202 just in frontal and 88 just in mid-coronal sections (total 452). 
There were far fewer differentially expressed genes at 16 weeks (71 genes in both regions, 
30 in frontal only, 20 in mid-coronal only, total 121) or 21 weeks (63 genes in both regions, 
131 in frontal only, 47 in mid-coronal only, total 241).  
Ingenuity Pathway Analysis of all 452 differentially expressed genes at 5 weeks showed that 
these involved several functional pathways (Table 1), many of which remained affected at 16 
and 21 weeks (Table 2). A common feature in both brain regions was the striking over-
representation of genes for “neurological disease” (Figure 1) particularly those involved in 
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encephalopathy, stroke, depression and blood brain barrier leakage (Table 3; further details 
in Supplementary Tables 1 and 2).  
Network analysis of the differential gene expression showed significant up-regulation in 
SHRSP of transcription factors (Figure 2) including Fos, JunB, Btg2 and early growth 
response genes (Egr1, Egr2, Egr4), genes central to cell signalling (Pgs2 [Cox2], Nfkbia, 
Pten, Sgk1), and C3; others were down-regulated (e.g. insulin-like growth factors [Igf2], 
albumin [Alb], Gfap and Mmp14).    
Across all ages, biological pathway analysis using IPA showed that the most significantly 
differentially expressed genes were in the acute phase response signalling pathway, but 
other pathways including circadian rhythm and complement were also affected (Figure 3). In 
the acute phase pathway, complement factor 3 (C3) was up-regulated, whilst Alb and 
transcription factor 4 were down-regulated. All three components of the complement pathway 
(classic, lectin and alternate) were affected (C3 up-regulated, C2 and C4 down-regulated) 
(Figure 4). The top five affected pathways also included genes associated with tight junction 
structure and signalling in 16 and 21 week old SHRSP.  
Amongst the most highly up-regulated genes were (Table 4): rat genome database (RGD) 
gene 1564649 related to urinary albumin secretion (up ~48-fold); ribosomal protein S9 
(Rps9) a translation regulator involved in cell proliferation (up ~26-fold); and guanylate 
cyclase soluble subunit alpha-3 (Gucy1a3, up ~20-fold), the intracellular nitric oxide (NO) 
vascular smooth muscle receptor. Amongst the most down-regulated genes were: Alb (down 
~3-fold at all ages); arginine vasopressin (Avp, down 4-fold at 5 weeks); guanine nucleotide 
binding protein alpha inhibiting 1 (Gnai1, down 3-fold at 16 weeks); and oxytocin (down ~3-
fold at 21 weeks).  
Compared with previously observed protein immunoreactivity [15], we saw no differences in 
mRNA expression of claudin-5, collagen I or Iba-1. However, Mmp14 mRNA was down-
regulated in SHRSP at 5 weeks and matrix metalloproteinase 14 (MMP14) has been shown 
to have a key role in modulating vessel stability and vascular responses to tissue injury by 
interacting with vascular molecules [27]. Down-regulated Mbp mRNA expression (2.6-fold) at 
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21 weeks was consistent with previously observed reduced myelin basic protein (MBP) 
immunoreactivity at all ages [15]. No relevant immunohistochemistry antibody was available 
to test for differential protein expression of AVP or GUCY1a3, but the mRNA data were 
consistent with other results [20-22].  
qRT-PCR (Supplementary Table 3) confirmed the microarray data for: MMP14 (down 5-fold 
at 5 weeks, p<0.01); GFAP (down 2-fold at 5 weeks, p=0.01); and AVP (down 4-fold at 5 
weeks, p<0.001) (Figure 5). qRT-PCR did not confirm the Alb, Gucy1a3, Mbp or Gpr98 
findings. The Alb difference may be a ‘floor effect’ where low mRNA expression, detectable 
by the greater dynamic range of the mRNA microarray, was undetectable by qRT-PCR. 
Despite consistent >15 fold Gucy1a3 mRNA up-regulation in SHRSP at all ages in both brain 
sections, qRT-PCR showed no significant differences. Microarray and qRT-PCR probes 
examine different gene segments which are separated by >1000 nucleotides. Whole gene 
sequencing demonstrated a SNP in the 3’ un-translated region (UTR) of the Gucy1a3 gene 
at position 4379 (WKY cytosine, SHRSP thymine). Discrepancies between mRNA 
microarray, qRT-PCR and immunohistochemistry could be further explained either by a true 
functional difference caused by microRNA binding to the 3’UTR region [28], or by post-
translational modification [29]. Post-translational modification may be a result of over 
exposure to a neurotransmitter or increased levels of reactive oxygen species [30] known to 
be present in the SHRSP [22].  
 
Discussion 
Differential gene expression between SHRSP and WKY has been demonstrated, the top 10 
differentially expressed genes having fold changes >2.5, and passing a FDR of p<0.05. 
These differences were most pronounced at 5 weeks and diminished with age. The fact that 
the greatest difference in gene expression was seen in the youngest pre-hypertensive age 
group supports the hypothesis that there are genetic factors unrelated to primary 
hypertension that underlie susceptibility to damage to the neurovascular unit, and that some 
of these genes have reduced expression with ageing. It is possible that some of these 
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pathways are related to age-specific processes such as developmental growth, although 
further genome analysis is required to assess this.  
We demonstrate multiple transcription regulation differences across several key functional 
and biological pathways around the neurovascular unit that explain some of the SHRSP’s 
complex brain pathology. The major biological pathways affected were “neurological” and 
“inflammatory”. The most affected genes were generally conserved across all three ages 
examined. This constellation of differentially-expressed genes may together increase 
vulnerability to microvascular damage and stroke. Possible mechanisms which may be 
involved, suggested by the data from this study and immunohistochemistry [15], include: 
impaired endothelial integrity (reduced claudin 5, MMP14) increasing the vascular endothelial 
permeability to plasma components which damage the arteriolar wall and subsequently the 
perivascular brain; reduced albumin facilitates fluid exudation into the vessel wall and brain 
interstitium through impaired plasma osmotic pressure [31]; microglial inflammatory 
responses are heightened, reducing NO bioavailability due to increased NO degradation 
from superoxide species [22, 32-34]; myelination (decreased MBP) is impaired and gliosis 
(increased GFAP) is increased, worsening brain damage; impaired vasoregulation 
(decreased Avp and Gnai1) and possibly reduced NO bioavailablity (functional increase in 
NO receptor Gucy1a3) further increase vulnerability to ischaemia through impaired cerebral 
vasodilatation.  
Up-regulated inflammatory pathway genes indicate a chronically challenged immune system 
from early life also shown by others [12] which may trigger or accentuate the vascular and 
perivascular damage observed in older SHRSP compared with control strains. Several of the 
genes showing significant differential expression between SHRSP and WKY were 
downstream transcriptional targets of cAMP response element binding protein (CREB) 
particularly the transcription factors (Figure 6). Genes regulated by CREB have been 
implicated in vascular remodelling in salt-induced hypertensive disease [35]. We found no 
difference in mRNA expression of Creb1, but differential phosphorylation of Creb1, initiated 
by NO [36] could be the source of increased transcription factor expression, and if shown in 
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future experiments, would provide further evidence of a central role for altered intracellular 
NO signalling.  
Reduced Avp is consistent with reported abnormalities in STR-2 loci [19] and associated with 
time to first stroke in SHRSP [20], highlighting the importance of intact vasoregulation. 
Potential functional differences in Gucy1a3 are consistent with observed increases in 
endothelin 1A receptors [34] and lower bioavailability of NO in SHRSP due to increased NO 
degradation from superoxide species [22, 32, 33]. Gucy1a3 was also identified in a recent 
GWAS of blood pressure and cardiovascular disease risk in humans [37].  
The tight junction pathway defects concur with data from older SHRSP [38]. The strikingly 
and consistently abnormal acute phase response pathways concur with reports of proteinuria 
and raised serum inflammatory proteins prior to hypertension [39], although salt 
supplementation confounded these studies [12]. Increased complement and other 
inflammatory gene expression parallels the consistent observation of perivascular 
inflammation seen pathologically in humans for over a century [4]. Ten month old stroke-free 
SHRSP had elevated MBP in one study of rats from the same colony [40] in contrast to the 
present work. The rats in both studies were fed on the same diet and kept in identical 
conditions, so the different findings cannot be attributed to salt loading as in some earlier 
studies. The rats studied by Brittain et al [40] at 10 months were the minority of stroke-free 
survivors as about 70% of the Glasgow SHRSP colony have had stroke by nine months and 
died. As our rats were sacrificed young, we have no way of knowing if they were in the 70% 
that have stroke by nine months or not. Of note, we did find histological evidence of early 
arteriolar fibrinoid microvascular changes in one SHRSP used in the gene expression 
analysis (unpublished observation) in contrast to Brittain et al.  
Although in this study we had limited numbers of rats, we had control animals kept under 
identical conditions, carefully blinded all analyses, had immunohistochemistry from the same 
rats’ opposite hemispheres, and used multiple overlapping methods to check our findings. 
We consider this SHRSP rat data to be valid animal model data to help focus translation 
research. In humans, stroke is a complex multifactorial disease, making a complex 
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spontaneous disease model highly relevant. A large meta-analysis of stroke GWAS data by 
METASTROKE has emphasised the need for specific stroke subtyping and has strongly 
suggested that different pathogenic mechanisms underlie the different stroke subtypes [18]. 
The genetic architecture of most human cerebral small vessel stroke is unknown, hampered 
by imprecise stroke phenotyping and multiple accumulating ageing-related co-morbidities. 
Brain microarray studies in elderly patients with dementia show multiple vessel wall, 
endothelial and brain parenchymal abnormalities including endothelial leakage [41] but 
precipitating factors and underlying susceptibility are difficult to unravel from end-stage 
disease.  Human GWAS support the multifactorial nature of SVD [17]. Blood-brain barrier 
permeability is increased early in disease development in SHRSP [42], and is a key feature 
associated with human SVD in several primary studies [1]. Abnormal vasoregulation, long 
suspected in human SVD and associated with time to first stroke in SHRSP [19] could be the 
final factor that precipitates SVD brain lesions once the multifactorial milieu described above 
is established. Human data from the Leiden Longevity Study suggests that individuals who 
survive into late old age (equivalent to 10 months in SHRSP) are less susceptible to white 
matter damage and lacunar infarcts [43] and we would be interested to study older (10 
months) stroke-free SHRSP rats to assess myelin integrity.  
In summary, our data supports the multifactorial theory of SVD, with a number of genetic 
predispositions and biological pathways potentially contributing to the typical pathology. A 
similar targeted approach using new single cell mRNA technologies should be considered to 
determine if a similar pattern of low-level multifactorial defects in several components of the 
neurovascular unit might explain susceptibility to human SVD. 
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Figure 1a:               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1b:                    
 
Figure 1: Heat maps were generated using hierarchical clustering of all significantly 
differentially expressed Neurological Genes from individual biological replicates of 5 week old 
SHRSP and WKY animals. The relative expression of each gene is represented by colour 
intensity, where red is up and green is down –regulated in a) 79 genes from the frontal region 
and b) 48 genes identified in the mid-coronal region. 
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Figure 2: A network from the “neurological disorders” functional group, representing 
interactions between differentially expressed genes in SHRSP vs WKY rats at 5 weeks of 
age, generated by Ingenuity Pathway Analysis software. Genes highlighted in red are down 
regulated and in green are up regulated in SHRSP compared with WKY. Statistics quoted 
are from top to bottom – p value and fold change. Solid lines indicate direct interactions. 
Dotted lines indicate indirect interactions. Details of affected genes are given in 
Supplementary Tables 1 and 2. 
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Figure 3: Details of genes in the “acute phase response” biological pathway identified in 
Ingenuity Pathway Analysis, that are differentially expressed in the frontal section of SHRSP 
versus WKY rats at 5 weeks of age. Genes highlighted red are down regulated and in green 
are up regulated in SHRSP compared with WKY. Statistics quoted are from top to bottom – p 
value and fold change. Solid lines indicate direct interactions. Dotted lines indicate indirect 
interactions.  
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Figure 4: Details of genes in the “complement” biological pathway identified in Ingenuity 
Pathway Analysis, that are differentially expressed in the frontal section of SHRSP versus 
WKY rats at 5 weeks of age. Genes highlighted red are down regulated and in green are up 
regulated in SHRSP compared with WKY. Statistics quoted are from top to bottom – p value 
and fold change. Solid lines indicate direct interactions. Dotted lines indicate indirect 
interactions. 
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Figure 5: Validation of significant changes in gene expression of A) GFAP, B) MMP14 and C) 
AVP in 5 week old rats using qRT-PCR.  Bars represent the difference in fold change 
between WKY and SHRSP. Error bars represent the standard error of the mean. Each bar 
represents n=4 rats.  * = p<0.05. ** = p<0.01. *** = p<0.001. A) GFAP mRNA expression was 
significantly reduced in the frontal section of SHRSP. B) MMP14 mRNA expression was A
cc
ep
te
d 
A
rti
cl
e
 
 This article is protected by copyright. All rights reserved.  
25 
significantly reduced in the frontal section of SHRSP. C) AVP mRNA expression was 
significantly reduced in the mid-coronal section of SHRSP 
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Figure 6: Heat maps generated using hierarchical clustering of the median expression from 
5, 16 and 21 week SHRSP and WKY downstream transcriptional targets of cAMP response 
element binding protein (Creb). The relative expression of each probe is represented by 
colour intensity, where red is up and green is down –regulated in a) 17 genes from the frontal 
(F) region and b) 18 genes identified in the mid-coronal (M) region. Genes are listed on the 
right hand side. 
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Table 1: Summary of analysis of differential gene expression by functional group in frontal 
and mid-coronal sections of 5 week old SHRSP and WKY rats performed using Ingenuity 
Pathway Analysis. See Supplementary Table 1 for similar analysis in 16 and 21 week rats. 
 
 
Frontal Mid coronal 
# 
Molecules 
p-value 
# 
Molecules 
p-value 
Diseases and disorders 
Neurological disease 79 
1.51E-10-
1.44E-02 
48 
3.80E-07-
1.02E-02 
Genetic disorder 84 
1.92E-09-
1.44E-02 
41 
6.19E-06-
1.02E-02 
Skeletal and muscular 
disorders 
72 
1.92E-09-
1.44E-02 
50 
6.19E-06-
1.02E-02 
Connective tissue disorders 40 
3.82E-06-
1.44E-02 
NA NA 
Inflammatory disease 48 
3.82E-06-
1.44E-02 
NA NA 
Developmental disorder NA NA 34 
1.12E-05-
1.02E-02 
Organismal injury and 
abnormalities 
NA NA 18 
5.62E-05-
8.69E-03 
 
Molecular and cellular functions 
Gene expression 70 
7.55E-07-
1.44E-02 
54 
2.83E-08-
1.02E-02 
Cell death 86 
5.00E-06-
1.44E-02 
NA NA 
Cell morphology 60 
2.14E-05-
1.44E-02 
NA NA 
Carbohydrate metabolism 3 
2.90E-05-
1.44E-02 
26 
1.04E-06-
1.02E-02 
Lipid metabolism 21 
2.90E-05-
1.44E-02 
54 
5.18E-08-
1.02E-02 
Small molecule biochemistry NA NA 44 
5.18E-08-
1.02E-02 
Cellular growth and 
proliferation 
NA NA 66 
1.44E-06-
1.02E-02 
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Table 2: Summary of differential gene expression by functional group in frontal and mid-
coronal sections of 16 and 21 week old SHRSP and WKY rats, performed using Ingenuity 
Pathway Analysis (see Table 1 for similar analysis of differentially expressed genes at 5 
weeks).  
 
16 wk   
 
Frontal Mid coronal 
# 
Molecules 
p-value 
# 
Molecules 
p-value 
Diseases and disorders 
Inflammatory response 4 
7.68E-05 – 
4.99E-02 
6 
7.68E-05 – 
2.86E-02 
Neurological disease 22 
1.01E-03 - 
4.61E-02 
18 
5.06E-05 – 
3.91E-02 
Connective tissue 
disorders  
12 
1.77E-03 – 
2.86E-02 
NA NA 
Inflammatory disease  15 
1.77E-03 - 
4.99E-02 
NA NA 
Skeletal and muscular 
disorders 
14 
1.77E-03 – 
2.86E-02 
NA NA 
Psychological disorders NA NA 8 
5.06E-05 – 
7.23E-03 
Infectious disease NA NA 7 
1.38E-04 – 
2.86E-02 
Cardiovascular disease NA NA 6 
5.68E-04 – 
1.89E-02 
 
Molecular and cellular functions 
Amino acid metabolism 6 
7.68E-05 – 
4.61E-02 
4 
7.68E-05 – 
3.56E-02 
Drug metabolism 4 
7.68E-05 – 
2.12E-02 
4 
7.68E-05 – 
3.56E-02 
Molecular transport 11 
7.68E-05 - 
4.95E-02 
17 
7.68E-05 – 
4.26E-02 
Small molecule 
biochemistry  
16 
7.68E-05 - 
4.95E-02 
19 
7.68E-05 – 
4.61E-02 
Cell death 22 
3.10E-03 – 
4.61E-02 
NA NA 
Nucleic acid metabolism NA NA 6 
3.19E-04 – 
4.61E-02 
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21 wk   
 
Frontal Mid coronal 
# 
Molecules 
p-value 
# 
Molecules 
p-value 
Diseases and disorders 
Neurological disease 39 
5.83E-08 – 
2.19E-02 
31 
2.49E-07 – 
2.06E-02 
Skeletal and muscular 
disorders 
40 
6.18E-07 – 
2.19E-02 
29 
2.49E-07 – 
1.29E-02 
Hereditary disorder 34 
7.50E-06 – 
2.19E-02 
27 
2.49E-07 – 
1.50E-02 
Cardiovascular disease 15 
1.61E-04 – 
2.19E-02 
NA NA 
Developmental disorder 19 
3.20E-04 – 
2.19E-02 
14 
1.13E-04 – 
2.06E-02 
Inflammatory response NA NA 10 
1.01E-04 – 
2.06E-02 
 
Molecular and cellular functions 
Cell-to-cell signalling and 
interaction 
28 
5.52E-06 – 
2.19E-02 
NA NA 
Cell cycle 9 
5.38E-05 – 
1.68E-02 
NA NA 
Cellular assembly and 
organization 
28 
5.38E-05 – 
2.19E-02 
NA NA 
Cellular function and 
maintenance 
39 
1.61E-04 – 
2.12E-02 
NA NA 
Cell death 45 
3.40E-04 – 
2.19E-02 
NA NA 
Amino acid metabolism NA NA 6 
7.98E-06 – 
2.06E-02 
Small molecule 
biochemistry 
NA NA 21 
7.98E-06 – 
2.41E-02 
Cell signalling NA NA 11 
5.79E-05 – 
2.06E-02 
Molecular transport NA NA 22 
5.79E-05 – 
2.41E-02 
Vitamin and mineral 
metabolism 
NA NA 13 
5.79E-05 – 
2.18E-02 
NA: not applicable 
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Table 3: Details of some differentially expressed genes in the “neurological disorders” functional pathway identified in IPA related to 
encephalopathy, major depression, stroke and blood brain barrier leakage. More details of Neurological and Inflammatory pathways affected 
are provided in Supplementary Tables 1 and 2. 
 
Functions Annotation p-Value 
Predicted 
Activation 
State 
Regulation 
z-score Molecules  
Encephalopathy 1.51E-10   -0.706 
ALB, BHLHE40, C20orf7, C3, C4B (includes others), CTGF, DUSP1, EGR1, EGR2, EGR4, 
FAM173A, FGF12, FGF13, FKBP8, FOS, FOXG1, GABRA5, GFAP, GOLPH3, GPR98, HLA-
DMA, IER5, JUNB, KCNC2, MAL2, MAP1B, MAP4K1, MYO1B, MYT1L, NFIA, NFIB, NGFR, 
PDCL, PDE10A, PGRMC1, PLCB1, PLP1 (includes EG:18823), POLL, POLR2I, PTEN, 
PTGS2, S100B, SCN2A, SCN3A, SCOC, SERPINI1, SGK1, SLC1A3, SNAP25, SSR3, 
STK17B, VSNL1, ZNF440/ZNF808 3 
Major depression 1.78E-03     BTG2, C7orf23, GABRA5, GFAP, IGFBP2, PDE10A, PSIP1, SYMPK, TTR 
Stroke 1.95E-03     ALB, GABRA5, NGFR, PTGS2, S100B, SNAP25, VSNL1 
Leakage of blood-brain 
barrier 2.01E-03     PTGS2, SERPINI1 
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Table 4: The top 10 up- and down-regulated genes in SHRSP versus WKY in each brain section and for each age group. All genes listed are 
significantly differentially expressed when a FDR of p<0.05 is applied.   
 FRONTAL SECTION MID CORONAL SECTION 
Age Up regulated  Fold change Down regulated Fold change  Up regulated Fold change Down regulated 
Fold 
change 
5 
RGD1564649 
Rps9 
Gucy1a3 
Fam151b 
RGD1311103 
Arc 
Znf597 
Rnf149 
Junb 
Znf317 
x48.1 
x26.4 
x21.8 
x8.3 
x4.9 
x4.4 
x4.1 
x3.9 
x3.5 
x3.4 
Mrpl18 
HCG 2004593 
RGD1565336 
Ttr 
Gpr98 
LOC100125697 
Alb 
Colq 
Pxmp4 
HLA-C 
x27.7 
x16.4 
x5.3 
x3.4 
x3.3 
x3.2 
x3.1 
x2.9 
x2.8 
x2.6 
RGD1564649 
Rps9 
Gucy1a3 
Fam151B 
RGD1311103 
Znf597 
Rnf149 
Arc 
Dusp1 
Rps16 
x59.7 
x25.6 
x23.0 
x6.7 
x4.9 
x4.2 
x4.1 
x3.9 
x3.1 
x3.0 
Mrpl18 
HCG 2004593 
RGD1565336 
Avp 
LOC100125697 
Gpr98 
Pxmp4 
Csnk2a1 
Vps13c 
C20orf7 
x29.1 
x13.2 
x4.6 
x4.3 
x3.5 
x3.2 
x3.1 
x2.6 
x2.6 
x2.5 
16 
RGD1564649 
Rps9 
Gucy1a3 
Fam151B 
RGD1311103 
Znf597 
Rps16 
RGD1566136 
x46.7 
x24.0 
x19.8 
x8.8 
x5.4 
x4.0 
x3.1 
x2.8 
Mrpl18 
HCG 2004593 
RGD1565336 
LOC100125697 
Pxmp4 
Alb 
Gpr98 
Gnai1 
x25.4 
x12.3 
x4.7 
x4.0 
x3.9 
x3.7 
x3.2 
x3.0 
RGD1564649 
Rps9 
Gucy1a3 
Fam151b 
RGD1311103 
Znf597 
Avp 
RGD1566136 
x54.5 
x27.2 
x14.5 
x7.9 
x6.6 
x4.0 
x3.8 
x3.0 
Mrpl18 
HCG 2004593 
RGD1565336 
Gpr8 
Alb 
LOC100125697 
Vps13c 
Csnk2a1 
x31.4 
x12.9 
x5.4 
x3.7 
x3.7 
x3.6 
x3.3 
x3.3 A
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HLA-C 
Adpgk 
x2.8 
x2.7 
C7orf23 
RGD1564078 
x2.9 
x2.8 
Rsp16 
HLA-C 
x2.9 
x2.8 
Pxmp4 
C7orf23 
x3.1 
x3.0 
21 
RGD1564649 
Gucy1a3 
RSP9 
Fam151b 
RGD1311103 
Znf597 
RGD1566136 
Rnf149 
Rps16 
HLA-C 
x46.9 
x20.3 
x18.8 
x7.3 
x6.6 
x4.8 
x3.7 
x3.4 
x3.2 
x2.8 
Mrpl18 
HCG 2004593 
Ttr 
RGD1565336 
Alb 
Gpr98 
Pxmp4 
Opcml 
Actb 
LOC100125697 
x30.7 
x11.3 
x7.4 
x3.9 
x3.8 
x3.8 
x3.6 
x3.6 
x3.4 
x3.2 
RGD1564649 
Gucy1a3 
Rsp9 
Fam151b 
RGD1311103 
Znf597 
Ttr 
Rnf149 
Adpgk 
HLA-C 
x45.6 
x20.7 
x18.9 
   x7.3 
   x4.8 
x4.5 
x3.7 
x3.4 
x3.4 
x3.3 
Mrpl18 
HCG 2004593 
RGD1565336 
Gpr98 
Oxt 
Alb 
Mobp 
LOC100125697 
Pxmp4 
Vps13c 
x25.9 
x14.1 
   x4.7 
x4.3 
x3.4 
x3.3 
x3.2 
x3.1 
x3.0 
x2.8 
 
RGD = rat genome database. Rps9 = ribosomal protein S9. Gucy1a3 = guanylate cyclase 1, soluble, alpha 3. Fam151b = family with sequence 
similarity 151, member B. Arc = activity-regulated cytoskeleton-associated protein. Znf = zinc finger protein. Rnf149 = ring finger protein 149. 
Junb = jun B proto-oncogene. Mrpl18 = mitochondrial ribosomal protein L18. Hcg = human chorionic gonadotrophin. Avp = arginine 
vasopressin. LOC = location. Gpr = G-protein coupled receptor.  Alb = albumin. Colq = collagen-like tail subunit of asymmetric 
acetylcholinesterase. Pxmp4 = peroxisomal membrane protein 4. Csnk2a1 = casein kinase 2, alpha 1 polypeptide. Vps13c = vacuolar protein 
sorting 13 homolog C. C20orf7 = chromosome 20 open reading frame 7. Hla-c = myosin heavy chain class 1 receptor C. Adpgk = ADP-
dependent glucokinase. C7orf23 = chromosome 7 open reading frame 23. Gnai1 = guanine nucleotide binding protein, alpha inhibiting 1. Opcml 
= opioid binding protein/cell adhesion molecule-like.  Actb = beta actin. Oxt = oxytocin. Mobp = myelin-associated oligodendrocyte basic protein. 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1: Details of differentially expressed genes in the “neurological disorders” functional pathway identified in IPA.  
 
Functions Annotation p-Value 
Predicted 
Activation 
State 
Regulation 
z-score Molecules 
# 
Molecules 
Encephalopathy 1.51E-10   -0.706 
ALB, BHLHE40, C20orf7, C3, C4B (includes others), CTGF, DUSP1, 
EGR1, EGR2, EGR4, FAM173A, FGF12, FGF13, FKBP8, FOS, FOXG1, 
GABRA5, GFAP, GOLPH3, GPR98, HLA-DMA, IER5, JUNB, KCNC2, 
MAL2, MAP1B, MAP4K1, MYO1B, MYT1L, NFIA, NFIB, NGFR, PDCL, 
PDE10A, PGRMC1, PLCB1, PLP1 (includes EG:18823), POLL, POLR2I, 
PTEN, PTGS2, S100B, SCN2A, SCN3A, SCOC, SERPINI1, SGK1, 
SLC1A3, SNAP25, SSR3, STK17B, VSNL1, ZNF440/ZNF808 53 
Huntington's disease 1.92E-09     
BHLHE40, C3, C4B (includes others), CTGF, EGR1, EGR2, EGR4, 
FAM173A, FGF12, FGF13, FOS, FOXG1, GABRA5, GFAP, IER5, JUNB, 
MAL2, MYO1B, MYT1L, PDCL, PDE10A, PGRMC1, PLCB1, POLR2I, 
SCN2A, SCN3A, SCOC, SERPINI1, SGK1, SLC1A3, SNAP25, SSR3, 
VSNL1, ZNF440/ZNF808 34 
Neuromuscular disease 2.95E-08     
ALB, BHLHE40, C3, C4B (includes others), COLQ, CTGF, EGR1, EGR2, 
EGR4, FAM173A, FGF12, FGF13, FOS, FOXG1, GABRA5, GFAP, HLA-
DMA, IER5, JUNB, MAL2, MAP1B, MYO1B, MYT1L, NGFR, PDCL, 
PDE10A, PGRMC1, PLCB1, POLR2I, PTGS2, S100B, SCN2A, SCN3A, 
SCOC, SERPINI1, SGK1, SLC1A3, SNAP25, SSR3, VSNL1, 
ZNF440/ZNF808 41 
Movement disorder 3.96E-07     
BHLHE40, C3, C4B (includes others), CTGF, EGR1, EGR2, EGR4, 
FAM173A, FGF12, FGF13, FOS, FOXG1, GABRA5, GFAP, IER5, JUNB, 
KCNC2, MAL2, MAP1B, MYO1B, MYT1L, NGFR, PDCL, PDE10A, 
PGRMC1, PLCB1, PLP1 (includes EG:18823), POLR2I, PTGS2, SCN2A, 
SCN3A, SCOC, SERPINI1, SGK1, SLC1A3, SNAP25, SSR3, VSNL1, 
ZNF440/ZNF808 39 
Seizures 8.58E-06 Increased 2.135 
BHLHE40, C3, FOS, GABRA5, GJC2, GPR98, KCNC2, MAP1B, NGFR, 
PLCB1, PLCL1, PTEN, PTGS2, SCN2A, SLC1A3, TRIM3 16 
Multiple system atrophy 5.70E-04     C20orf7, SCN2A, SCN3A, SLC1A3 4 A
cc
ep
te
d 
A
rti
cl
e
 
 This article is protected by copyright. All rights reserved.  
33 
Pelizaeus-Merzbacher 
disease 1.22E-03     GJC2, PLP1 (includes EG:18823) 2 
Major depression 1.78E-03     BTG2, C7orf23, GABRA5, GFAP, IGFBP2, PDE10A, PSIP1, SYMPK, TTR 9 
Stroke 1.95E-03     ALB, GABRA5, NGFR, PTGS2, S100B, SNAP25, VSNL1 7 
Leakage of blood-brain 
barrier 2.01E-03     PTGS2, SERPINI1 2 
Allodynia 2.34E-03     PTGDS, PTGS2, S100B, SLC1A3 4 
Agenesis of corpus 
callosum 4.15E-03     MAP1B, NFIB 2 
Hyperproliferation of 
brain cells 4.15E-03     BTG2, SSTR2 2 
Cerebellar ataxia 4.24E-03     SCN2A, SCN3A, SLC1A3 3 
Fragile X syndrome 4.24E-03     SCN2A, SCN3A, SLC1A3 3 
Amyotrophic lateral 
sclerosis 4.73E-03     GABRA5, GFAP, NGFR, PTGS2, SCN2A, SCN3A, SLC1A3 7 
Cervical spondylotic 
myelopathy 4.80E-03     SCN2A, SCN3A, SLC1A3 3 
Tumorigenesis of brain 
cells 5.48E-03     MYCN, SSTR2 2 
Neurodegenerative 
disorder 7.88E-03     
C20orf7, C3, CTGF, GABRA5, GFAP, GJC2, IGF2, IGFBP2, IGFBP6, 
NGFR, PLP1 (includes EG:18823), PTEN, PTGDS, PTGS2, SCN2A, 
SCN3A, SLC1A3, TTR 18 
Schizophrenia 8.64E-03     
EGR4, GABRA5, GFAP, GNAI1, MLLT11, NFKBIA, NPTN, PLP1 (includes 
EG:18823), PNPLA8, PTGS2, S100B, SERPINI1, SLC1A3, SNAP25, TTR, 
VSNL1 16 
Age-related macular 
degeneration 9.89E-03     C2, C3, CFH 3 
Progressive 
supranuclear palsy 9.89E-03     SCN2A, SCN3A, SLC1A3 3 
Macrocephaly 1.05E-02     POLL, PTEN 2 
Brain cancer 1.25E-02     BTG2, FOXG1, GFAP, IGF2, IGFBP2, MCL1, MMP14, MYCN, PTEN 9 
Hydrocephalus 1.29E-02     GFAP, NFIA, POLL, S100B 4 
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Neuropathy 1.40E-02     
EGR1, EGR2, GABRA5, GFAP, HLA-DMA, MAP1B, NGFR, PLP1 
(includes EG:18823), PTGS2, SCN2A, SCN3A, SGK1, SLC1A3, SNAP25, 
TTR 15 
Cockayne syndrome 
type I 1.44E-02     ERCC8 1 
Lhermitte-Duclos 
disease 1.44E-02     PTEN 1 
Macrocephal-autism 
syndrome 1.44E-02     PTEN 1 
Pelizaeus-Merzbacher-
like disease 1.44E-02     GJC2 1 
Pitt-Hopkins syndrome 1.44E-02     TCF4 1 
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Supplementary Table 2: Details of differentially expressed genes in the “inflammation” functional pathway identified in IPA.  
Functions Annotation p-Value 
Predicted 
Activation 
State 
Regulation 
z-score Molecules 
# 
Molecules 
Rheumatic disease 3.82E-06   0.071 
ALB, C2, C3, C4B (includes others), CLIC2, COL3A1, COL6A1, CPE (includes 
EG:12876), DUSP1, EGR2, FOS, GABRA5, GALNT2, GOLPH3, HLA-C, HLA-MA, 
MAP4K1, MAPRE1, MCL1, MMP14, NFKBIA, NGFR, NR4A3, PHACTR3, PTEN, 
PTGDS, PTGS2, RALB, RNF149, RNF39, RPS16, RPS18, SCN2A, SCN3A, 
SLC1A3, SNAP25, STK17B, TCF4, VPS52 (includes EG:224705) 39 
Arthritis 1.32E-05   0.449 
ALB, C2, C3, C4B (includes others), CLIC2, COL3A1, COL6A1, CPE (includes 
EG:12876), DUSP1, FOS, GABRA5, GALNT2, GOLPH3, HLA-C, HLA-DMA, 
MAP4K1, MAPRE1, MCL1, MMP14, NFKBIA, NGFR, NR4A3, PHACTR3, PTEN, 
PTGDS, PTGS2, RALB, RNF149, RNF39, RPS16, RPS18, SNAP25, STK17B, 
TCF4, VPS52 (includes EG:224705) 35 
Rheumatoid arthritis 7.55E-05     
ALB, C2, C4B (includes others), CLIC2, COL3A1, DUSP1, FOS, GABRA5, GALNT2, 
GOLPH3, HLA-C, HLA-DMA, MAPRE1, MCL1, NFKBIA, NGFR, NR4A3, PHACTR3, 
PTGS2, RALB, RNF149, RNF39, RPS16, RPS18, STK17B, TCF4, VPS52 (includes 
EG:224705) 27 
Juvenile rheumatoid 
arthritis 3.11E-04     ALB, CLIC2, FOS, MCL1, NFKBIA, NR4A3, PTGS2, RALB 8 
Polyarticular juvenile 
rheumatoid arthritis 1.61E-03     FOS, MCL1, NFKBIA, NR4A3, PTGS2, RALB 6 
Splenomegaly 3.82E-03   -0.417 C3, C4B (includes others), INPP5D, NFKBIA, PTEN 5 
Pulmonary interstitial 
fibrosis 4.15E-03     EGR1, PTGS2 2 
Cervical spondylotic 
myelopathy 4.80E-03     SCN2A, SCN3A, SLC1A3 3 
Acne 1.11E-02     COL3A1, CYP11B1, PLA2G2A, PTGS2, SGK1 5 
Lichen planus 1.43E-02     COL3A1, HBB, HLA-C, IFI27, IGFBP6 5 
Allergic contact eczema 1.44E-02     HLA-C 1 
Arthritis of bone 1.44E-02     MMP14 1 
Chronic suppurative 
sinusitis 1.44E-02     POLL 1 
Collagen-induced 
arthritis of ankle joint 1.44E-02     PTEN 1 
 
 A
cc
ep
te
d 
A
rti
cl
e
 
 This article is protected by copyright. All rights reserved.  
36 
Supplementary Table 3: Genes from the microarray chosen for quantitative validation with qRT-PCR, the reasons, and data obtained from qRT-
PCR analysis. Numbers are the mean difference (± the standard error of the mean) in CT values between the gene of interest and the house 
keeper gene GAPDH for SHRSP and WKY at ages 5-21 weeks and from frontal (F) and mid coronal (M) brain sections.  
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 Mean dCT ± standard error 
Gene 
Reason for validation of microarray 
data with qRT-PCR 
Age & 
Section 
5F 5M 16F 16M 21F 21M 
GUCY1a3 
Consistent up-regulation of over x15 fold 
change at all ages in both sections. 
SHRSP 5.39 ± 0.59 4.74 ± 0.11 3.70 ± 0.36 3.92 ± 0.37 3.36 ± 0.25 2.99 ± 0.27 
WKY 4.83 ± 0.28 5.07 ± 0.24 4.18 ± 0.05 3.66 ± 0.41 2.60 ± 0.18 3.56 ± 0.52 
p value NS NS NS NS 0.05 NS 
MMP14 
Direct interactions with other genes of 
interest and down-regulation at 5 weeks 
of age. At 5 weeks in the frontal section 
there was significantly less MMP14 gene 
expression in the SHRSP rats. 
SHRSP 11.29 ± 0.38 6.28 ± 0.28 1.81 ± 0.63 3.53 ± 0.94 3.38 ± 0.68 2.93 ± 0.17 
WKY 8.84 ± 0.12 7.43 ± 0.34 3.71 ± 0.55 3.72 ± 0.69 2.23 ± 0.70 3.57 ± 0.51 
p value <0.01 <0.05 NS NS NS NS 
GFAP 
To validate immunohistochemistry 
findings and significantly down-regulated 
at 5 weeks on the microarray. 
SHRSP 5.07 ± 0.25 3.44 ± 0.17 4.03 ± 0.51 3.21 ± 0.49 3.87 ± 0.32 3.46 ± 0.30 
WKY 3.85 ± 0.26 2.92 ± 0.31 4.23 ± 0.36 3.42 ± 0.44 3.20 ± 0.36 3.43 ± 0.17 
p value <0.05 NS NS NS NS NS 
ALB 
Consistently down-regulated at all ages 
and in both sections of SHRSP. 
SHRSP 6.59 ± 1.16 4.80 ± 1.38 5.94 ± 0.91 5.99 ± 0.72 3.60 ± 1.08 6.13 ± 1.53 
WKY 10.98 ± 1.24 9.33 ± 0.72 7.67 ± 0.55 6.05 ± 1.04 5.78 ± 0.97 5.42 ± 1.11 
p value <0.05 <0.05 NS NS NS NS 
AVP 
Significant down regulation at 5 weeks 
and relevant to vasoactive mechanisms.  
SHRSP 10.90 ± 0.52 2.49 + 0.36 
N/A  WKY 10.33 ± 0.59 0.56 ± 0.34 
p value NS <0.01 
GPR98 
Significant down regulation across all 
ages. 
SHRSP 
N/A 
8.11 + 1.19 6.93 + 0.92 
N/A WKY 9.15 + 0.75 7.27 + 1.00 
p value NS NS 
MBP 
Significant down-regulation and in 
protein expression at 21 weeks on 
immunohistochemistry  
SHRSP 
N/A 
-0.19 ± 0.75 -0.21 ± 0.21 
WKY -0.94 ± 0.74 -0.17 ± 0.62 
p value NS NS 
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